3rd
- Title: Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks
Presenter:Mauro Cancian , M.D., Ph.D.
Format: Poster Presentation
Date, time:Friday, March 15 ,4:30 p.m. CET (11:30 a.m. EDT ) - Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Presenter:Giuseppe Spadaro , M.D., Ph.D.
Format: Poster Presentation
Date, time:Friday, March 15 ,4:30 p.m. CET (11:30 a.m. EDT ) - Title: Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema
Presenter:Andrea Zanichelli , M.D., Ph.D.
Format: Poster Presentation
Date, time:Friday, March 15 ,4:30 p.m. CET (11:30 a.m. EDT ) - Title: Need for Caregiver Support for People Living With Hereditary Angioedema in European Countries
Presenter:Andrea Zanichelli , M.D., Ph.D.
Format: Poster Presentation
Date, time:Friday, March 15 ,4:30 p.m. CET (11:30 a.m. EDT ) - Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presenter:Mauro Cancian , M.D., Ph.D.
Format: Selected Oral and Poster Presentation
Date, time:Saturday, March 16 ,10:00 a.m. CET (5:00 a.m. EDT )
2024 HAEi Regional Conference Americas,
- Title: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
Presenter:Anete Grumach , M.D., Ph.D.
Format: Poster Presentation
Date, time:Friday, March 15 ,7:20 p.m. EDT - Title: Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Presenter:Markus Magerl , M.D.
Format: Poster Presentation
Date, time:Friday, March 15 ,7:20 p.m. EDT - Title: Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
Presenter:Marcus Maurer , M.D.
Format: Poster Presentation
Date, time:Friday, March 15 ,7:20 p.m. EDT - Title: Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
Presenter:Marc A. Riedl , M.D., M.S.
Format: Oral Presentation
Date, time:Saturday, March 16 ,9:30 a.m. EDT - Title: Understanding
Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from aReal World Survey
Presenter:William Lumry , M.D.
Format: Oral Presentation
Date, time:Saturday, March 16 ,11:15 a.m. EDT
The posters and presentation slides will be made available on the Investors section of the
About
Building on its deep-seated roots in HAE,
Contact
Executive Director, Head of
maggie.beller@pharvaris.com
Source:
2024 GlobeNewswire, Inc., source